You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金活醫藥集團(01110.HK)訂立獨家分銷協議推廣馬來酸依那普利葉酸片
格隆匯 10-30 21:04

格隆匯10月3日丨金活醫藥集團(01110.HK)公告,於2020年10月30日,公司全資附屬公司深圳市金活醫藥有限公司與深圳奧薩製藥有限公司訂立獨家分銷協議,內容有關在中國內地市場推廣及分銷10.4毫克馬來酸依那普利葉酸片。

根據該協議,奧薩已委任深圳金活為其在中國內地推廣、銷售及分銷該產品的獨家分銷商,為期五年。初始五年期限屆滿後,該協議可自動續期五年。通過戰略性地利用其市場網絡,公司旨在於中國內地的高血壓藥物市場上建立該產品的強大地位。

根據奧薩提供的資料,馬來酸依那普利葉酸片是一種專為有效控制H型高血壓而設計的多風險因素控制性創新預防複合處方藥。該產品已被歸類為國家一類新藥(化學藥品)並被納入中國國家基本醫療保險、工傷保險和生育保險藥品目錄(2009)。

奧薩為一家致力於醫療及診斷產品的研發及商業化的製藥公司,其總部位於中國廣東省深圳市。

公司表示,通過利用其商業平台、廣泛的分銷網絡和豐富的營銷策略,集團的目標為令該產品的價值及市場潛力最大化,併為廣大的H型高血壓患者提供服務。董事會認為,訂立該協議將進一步擴大集團的產品組合及充分利用於蓬勃發展的中國市場中消費者對醫藥產品不斷增長的需求,從而鞏固其市場地位,此舉將對集團及公司股東整體有利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account